Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) presented five-year data from its Phase 2 C-144-01 trial of Amtagvi (lifileucel) during the 2025 ASCO Annual Meeting.

A medical staff in white coats monitoring the progress of cancer immunotherapy trials.

A five-year overall survival rate of 19.7% and a median overall survival of 13.9 months were reported in 153 patients with advanced melanoma who had previously received anti-PD-1 and targeted treatments. The intended response rate was 31.4%, with a median response duration of 36.5 months, and 5.9% complete and 25.5% partial responses. At five years, 31.3% of respondents remained active. There were no novel late-onset adverse events, and safety results were in line with established profiles of IL-2 and lymphodepletion. Amtagvi is still the only one-time T cell treatment for solid tumors that has received FDA approval.

In February 2024, Amtagvi was given accelerated FDA approval for melanoma that was metastatic or unresectable following PD-1 and targeted treatments. Patients who had not responded to at least one systemic treatment were selected for the vital C-144-01 trial. Cohorts 2 and 4 of the trial followed the identical manufacturing method and regimen.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s TIL platform, which targets a market where 90% of cancers are solid tumors, is the first to be approved for solid tumors. Tumor tissue is surgically removed, billions of T cells are produced in 34 days, and then the cells are infused following lymphodepletion and IL-2.

Moreover, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is assessing lifileucel in NSCLC and conducting the TILVANCE-301 Phase 3 trial in frontline melanoma.

While we acknowledge the potential of IOVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than IOVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.